ELIMINATION OF ANTIGEN REACTIVE B CELLS

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 7897
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Awards Year: 1988
Solitcitation Year: N/A
Solitcitation Topic Code: N/A
Solitcitation Number: N/A
Small Business Information
Medarex Inc
1401 Broad St, Clifton, NJ, 07015
Duns: N/A
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 () -
Business Contact
Phone: () -
Research Institution
N/A
Abstract
MEDAREX HAS EXCLUSIVE LICENSE TO SEVERAL MONOCLONAL ANTIBODIES (MABS) REACTIVE TO THE HIGH AFFINITY FC RECEPTOR FOR IGG (FCGRI), ON HUMAN MONOCYTES. THIS RECEPTOR IS A CRITICAL TRIGGER MOLECULE FOR ADCC BY THESE CELLS AND HAS BEEN SHOWN TO MEDIATE KILLING OF RED CELL TARGETS AND TUMOR LIKE CELLS. WE PROPOSE TO DETERMINE THE FEASIBILITY OF USING THESE REAGENTS TO ELIMINATE ANTIGEN REACTIVE B CELLS. STUDIES BY CONSULTANTS TO MEDAREX INDICATE THAT THIS APPROACH PERMITS LYSIS OF B CELL-LIKE TARGETS (HYBRIDOMA CELLS EXPRESSING SURFACE IG). WE NOW PROPOSE TO DEMONSTRATETHAT NORMAL B CELLS REACTIVE TO PARTICULAR ANTIGENS CAN BE KILLED IN A SIMILAR FASHION. OUR SPECIFIC AIMS ARE, THEREFORE, TO INVESTIGATE, USING AN IN VITRO MOUSE MODEL SYSTEM, WHETHER OUR ANTI-FCGRI MABS, WHEN COUPLED TO ANTIGEN (TNP) CAN 1) MEDIATE KILLING OF RESTING ANTIGEN REACTIVE B CELLS BY HUMAN MONOCYTES; 2) TARGET HUMAN MONOCYTES TO ELIMINATE ANTIGEN REACTIVE B CELLS; AND 3) MEDIATE ELIMINATION OF PLAQUE FORMING CELLS.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government